0 XP   0   0   0

Basilea Pharmaceutica AG
Buy or Sell?

Welcome Invester! I guess you are interested in Basilea Pharmaceutica AG. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's start. I'm going to help you getting a better view of Basilea Pharmaceutica AG. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Basilea Pharmaceutica AG even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Basilea Pharmaceutica AG is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Basilea Pharmaceutica AG. The closing price on 2022-09-29 was CHF38.15 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Basilea Pharmaceutica AG Daily Candlestick Chart


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

1.1. Profitability of Basilea Pharmaceutica AG.

1.1. Profitability

An important factor of a company's health is the profitability.

1.1.1. Net Profit Margin

Measures how much net profit Basilea earns for each CHF1 of revenue.

  • Above 10% is considered healthy but always compare Basilea to the Biotechnology industry mean.
  • A Net Profit Margin of 3.5% means that CHF0.03 for each CHF1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Basilea Pharmaceutica AG:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM3.5%-3.5%
TTM3.5%YOY-19.8%+23.2%
TTM3.5%5Y-10.1%+13.5%
5Y-10.1%10Y-45.6%+35.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--236.6%+236.6%
TTM3.5%-275.9%+279.4%
YOY-19.8%-342.0%+322.2%
5Y-10.1%-475.7%+465.6%
10Y-45.6%-561.7%+516.1%
1.1.2. Return on Assets

Shows how efficient Basilea is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Basilea to the Biotechnology industry mean.
  • 2.0% Return on Assets means that Basilea generated CHF0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Basilea Pharmaceutica AG:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.0%-2.0%
TTM2.0%YOY-4.9%+6.9%
TTM2.0%5Y-1.2%+3.3%
5Y-1.2%10Y-2.5%+1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--9.7%+9.7%
TTM2.0%-8.7%+10.7%
YOY-4.9%-9.2%+4.3%
5Y-1.2%-11.5%+10.3%
10Y-2.5%-12.4%+9.9%
1.1.3. Return on Equity

Shows how efficient Basilea is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Basilea to the Biotechnology industry mean.
  • 0.0% Return on Equity means the company generated CHF0.00 for each CHF1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Basilea Pharmaceutica AG:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM11.0%-11.0%
TTM11.0%YOY-+11.0%
TTM11.0%5Y3.9%+7.1%
5Y3.9%10Y-10.6%+14.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--11.8%+11.8%
TTM11.0%-11.0%+22.0%
YOY--10.7%+10.7%
5Y3.9%-13.5%+17.4%
10Y-10.6%-14.5%+3.9%

1.2. Operating Efficiency of Basilea Pharmaceutica AG.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Basilea is operating .

  • Measures how much profit Basilea makes for each CHF1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Basilea to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated CHF0.00  for each CHF1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Basilea Pharmaceutica AG:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.3%-2.3%
TTM2.3%YOY-7.7%+10.0%
TTM2.3%5Y-6.0%+8.3%
5Y-6.0%10Y-41.9%+35.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--232.1%+232.1%
TTM2.3%-269.6%+271.9%
YOY-7.7%-307.9%+300.2%
5Y-6.0%-466.7%+460.7%
10Y-41.9%-566.6%+524.7%
1.2.2. Operating Ratio

Measures how efficient Basilea is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.0% means that the operating costs are CHF0.00for each CHF1 in net sales.

Let's take a look of the Operating Ratio trends of Basilea Pharmaceutica AG:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.028-0.028
TTM0.028YOY0.109-0.081
TTM0.0285Y0.680-0.652
5Y0.68010Y0.833-0.153
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.321-3.321
TTM0.0283.542-3.514
YOY0.1093.491-3.382
5Y0.6805.741-5.061
10Y0.8336.934-6.101

1.3. Liquidity of Basilea Pharmaceutica AG.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Basilea is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 136.2% means the company has CHF1.36 in assets for each CHF1 in short-term debts.

Let's take a look of the Current Ratio trends of Basilea Pharmaceutica AG:

  • The MRQ is 1.362. The company is just able to pay all its short-term debts.
  • The TTM is 1.372. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.362TTM1.372-0.010
TTM1.372YOY5.148-3.776
TTM1.3725Y3.433-2.060
5Y3.43310Y3.120+0.313
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3625.282-3.920
TTM1.3726.060-4.688
YOY5.1486.365-1.217
5Y3.4336.692-3.259
10Y3.1206.457-3.337
1.3.2. Quick Ratio

Measures if Basilea is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy (always compare to Biotechnology industry mean)
  • A Quick Ratio of 176.5% means the company can pay off CHF1.76 for each CHF1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Basilea Pharmaceutica AG:

  • The MRQ is 1.765. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.037. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.765TTM1.037+0.727
TTM1.037YOY3.633-2.596
TTM1.0375Y2.411-1.374
5Y2.41110Y2.614-0.202
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7653.996-2.231
TTM1.0374.882-3.845
YOY3.6335.192-1.559
5Y2.4115.275-2.864
10Y2.6144.997-2.383

1.4. Solvency of Basilea Pharmaceutica AG.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Basilea assets are financed with debt.

  • Below 1 (100%) is considered healthy (always compare to Biotechnology industry mean).
  • A Debt to Asset Ratio of 1.28 means that Basilea assets are financed with 128.5% credit (debt) and the remaining percentage (100% - 128.5%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Basilea Pharmaceutica AG:

  • The MRQ is 1.285. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.276. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.285TTM1.276+0.008
TTM1.276YOY1.410-0.133
TTM1.2765Y1.309-0.033
5Y1.30910Y1.086+0.223
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2850.270+1.015
TTM1.2760.269+1.007
YOY1.4100.296+1.114
5Y1.3090.362+0.947
10Y1.0860.399+0.687
1.4.2. Debt to Equity Ratio

Measures if Basilea is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy (always compare to Biotechnology industry mean).
  • A Debt to Equity ratio of 0.0% means that company has CHF0.00 debt for each CHF1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Basilea Pharmaceutica AG:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM10.296-10.296
TTM10.296YOY10.239+0.056
TTM10.2965Y5.165+5.130
5Y5.16510Y5.572-0.407
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.310-0.310
TTM10.2960.311+9.985
YOY10.2390.310+9.929
5Y5.1650.382+4.783
10Y5.5720.438+5.134

2. Market Valuation of Basilea Pharmaceutica AG

2. Earnings
2.1. Price to Earnings Ratio

Measures how many years it takes to double your invested money in Basilea.

  • Above 15 is considered overpriced but is hard to determine (always use industry average).
  • A PE ratio of 316.80 means the investor is paying CHF316.80 for every CHF1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Basilea Pharmaceutica AG:

  • The EOD is 313.108. Seems overpriced? -1
  • The MRQ is 316.801. Seems overpriced? -1
  • The TTM is 25.972. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD313.108MRQ316.801-3.693
MRQ316.801TTM25.972+290.830
TTM25.972YOY-31.379+57.351
TTM25.9725Y-60.005+85.977
5Y-60.00510Y-33.147-26.858
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD313.108-2.150+315.258
MRQ316.801-2.332+319.133
TTM25.972-3.889+29.861
YOY-31.379-5.074-26.305
5Y-60.005-3.680-56.325
10Y-33.147-3.374-29.773
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Basilea.

  • Lower is better
  • A PEG ratio of 1 means the investor is paying a fair price for the stock

Let's take a look of the Price Earnings to Growth Ratio trends of Basilea Pharmaceutica AG:

  • The MRQ is -3.077. Very Bad. -2
  • The TTM is -0.121. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-3.077TTM-0.121-2.956
TTM-0.121YOY0.276-0.397
TTM-0.1215Y0.516-0.637
5Y0.51610Y0.462+0.054
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.0770.004-3.081
TTM-0.1210.020-0.141
YOY0.2760.041+0.235
5Y0.5160.020+0.496
10Y0.4620.017+0.445

2. Books
2.3. Price to Book Ratio

Measures if the stock price of Basilea is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -6.81 means the investor is paying CHF-6.81 for each CHF1 in book value.

Let's take a look of the Price to Book Ratio trends of Basilea Pharmaceutica AG:

  • The EOD is -6.730. Bad. Book ratio is negative. -2
  • The MRQ is -6.809. Bad. Book ratio is negative. -2
  • The TTM is -7.122. Bad. Book ratio is negative. -2
Trends
Current periodCompared to+/- 
EOD-6.730MRQ-6.809+0.079
MRQ-6.809TTM-7.122+0.312
TTM-7.122YOY-5.929-1.192
TTM-7.1225Y-8.276+1.154
5Y-8.27610Y-3.651-4.625
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.7301.816-8.546
MRQ-6.8091.961-8.770
TTM-7.1222.789-9.911
YOY-5.9293.538-9.467
5Y-8.2762.782-11.058
10Y-3.6512.419-6.070

2.4. Latest News of Basilea Pharmaceutica AG

Does Basilea Pharmaceutica AG still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Basilea Pharmaceutica AG to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2022-09-21
07:15
Basilea announces closing of CHF 75 million senior secured loan agreement with AthyriumRead
2022-09-07
07:15
Basilea announces CHF 75 million senior secured loan agreement with Athyrium for non-dilutive refinancing of convertible bonds due in December 2022Read

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Basilea Pharmaceutica AG compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Per Share---5.669-5.719+1%-8.349+47%-6.758+19%-1.483-74%
Current Ratio--1.3621.372-1%5.148-74%3.433-60%3.120-56%
Debt To Asset Ratio--1.2851.276+1%1.410-9%1.309-2%1.086+18%
Debt To Equity Ratio---10.296-100%10.239-100%5.165-100%5.572-100%
Eps---0.5150.030-1791%-1.027+99%-0.449-13%-0.476-8%
Gross Profit Margin---0.500-100%0.500-100%1.151-100%1.610-100%
Net Profit Margin---0.035-100%-0.1980%-0.1010%-0.4560%
Operating Margin---0.023-100%-0.0770%-0.0600%-0.4190%
Operating Ratio---0.028-100%0.109-100%0.680-100%0.833-100%
Pb Ratio-6.730+1%-6.809-7.122+5%-5.929-13%-8.276+22%-3.651-46%
Pe Ratio313.108-1%316.80125.972+1120%-31.379+110%-60.005+119%-33.147+110%
Peg Ratio---3.077-0.121-96%0.276-1216%0.516-696%0.462-766%
Price Per Share38.150-1%38.60040.035-4%48.860-21%49.998-23%66.650-42%
Quick Ratio--1.7651.037+70%3.633-51%2.411-27%2.614-32%
Return On Assets---0.020-100%-0.0490%-0.0120%-0.0250%
Return On Equity---0.110-100%-0%0.039-100%-0.1060%
 EOD+2 -1MRQTTM+6 -10YOY+8 -45Y+6 -710Y+5 -7

3.2. Fundamental Score

Let's check the fundamental score of Basilea Pharmaceutica AG based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15313.108
Price to Book Ratio (EOD)Between0-1-6.730
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.765
Current Ratio (MRQ)Greater than11.362
Debt to Asset Ratio (MRQ)Less than11.285
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.050.000
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Basilea Pharmaceutica AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.219
Ma 20Greater thanMa 5038.998
Ma 50Greater thanMa 10040.150
Ma 100Greater thanMa 20037.703
OpenGreater thanClose38.000
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2022-06-30. Currency in CHF. All numbers in thousands.

Summary
Total Assets236,073
Total Liabilities303,239
Total Stockholder Equity-67,166
 As reported
Total Liabilities 303,239
Total Stockholder Equity+ -67,166
Total Assets = 236,073

Assets

Total Assets236,073
Total Current Assets211,789
Long-term Assets211,789
Total Current Assets
Cash And Cash Equivalents 45,746
Short-term Investments 94,990
Net Receivables 38,606
Inventory 24,754
Total Current Assets  (as reported)211,789
Total Current Assets  (calculated)204,096
+/- 7,693
Long-term Assets
Property Plant Equipment 21,644
Intangible Assets 1,247
Other Assets 152
Long-term Assets  (as reported)24,284
Long-term Assets  (calculated)23,043
+/- 1,241

Liabilities & Shareholders' Equity

Total Current Liabilities155,443
Long-term Liabilities147,796
Total Stockholder Equity-67,166
Total Current Liabilities
Short-term Debt 119,320
Short Long Term Debt 117,195
Accounts payable 4,706
Other Current Liabilities 31,417
Total Current Liabilities  (as reported)155,443
Total Current Liabilities  (calculated)272,638
+/- 117,195
Long-term Liabilities
Long term Debt 94,770
Capital Lease Obligations 19,344
Other Liabilities 35,807
Long-term Liabilities Other 24,498
Long-term Liabilities  (as reported)147,796
Long-term Liabilities  (calculated)174,419
+/- 26,623
Total Stockholder Equity
Common Stock12,999
Retained Earnings -1,035,428
Other Stockholders Equity 955,263
Total Stockholder Equity (as reported)-67,166
Total Stockholder Equity (calculated)-67,166
+/-0
Other
Capital Stock12,999
Cash and Short Term Investments 140,736
Common Stock Shares Outstanding 11,849
Liabilities and Stockholders Equity 236,073
Net Debt 185,563
Net Invested Capital 144,799
Net Tangible Assets -68,413
Net Working Capital 56,346
Short Long Term Debt Total 231,309



Balance Sheet

Currency in CHF. All numbers in thousands.

 Trend2022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-31
> Total Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
206,609
0
229,014
0
316,542
0
279,010
0
237,090
0
190,418
0
375,345
0
290,270
0
299,756
0
274,330
0
257,378
0
248,878
0
398,735
346,000
345,653
328,000
327,758
293,898
293,898
351,165
351,165
305,108
305,108
281,751
281,751
235,649
235,649
221,467
221,467
0
197,055
0
229,794
0
227,176
0
247,267
0
236,073
236,0730247,2670227,1760229,7940197,0550221,467221,467235,649235,649281,751281,751305,108305,108351,165351,165293,898293,898327,758328,000345,653346,000398,7350248,8780257,3780274,3300299,7560290,2700375,3450190,4180237,0900279,0100316,5420229,0140206,60900000000000000000000000000000000
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
185,913
0
209,597
0
299,567
0
262,134
0
219,413
0
174,172
0
360,175
0
276,203
0
286,167
0
261,371
0
244,571
0
234,616
0
384,865
283,000
283,004
268,000
268,494
235,328
235,328
292,976
292,976
247,480
247,480
274,738
274,738
228,268
228,268
184,860
184,860
161,010
161,010
223,528
223,528
220,189
220,189
241,066
241,066
211,789
211,789
211,789211,789241,066241,066220,189220,189223,528223,528161,010161,010184,860184,860228,268228,268274,738274,738247,480247,480292,976292,976235,328235,328268,494268,000283,004283,000384,8650234,6160244,5710261,3710286,1670276,2030360,1750174,1720219,4130262,1340299,5670209,5970185,91300000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
113,378
0
93,822
0
132,989
0
93,284
0
172,146
0
69,032
0
224,000
0
142,752
0
118,898
0
130,887
0
156,100
0
136,887
0
313,100
261,000
260,919
239,000
238,500
143,101
143,101
200,724
198,600
137,288
137,288
173,034
173,000
127,871
127,871
109,024
109,000
0
59,779
0
60,700
0
82,849
0
53,700
0
45,746
45,746053,700082,849060,700059,7790109,000109,024127,871127,871173,000173,034137,288137,288198,600200,724143,101143,101238,500239,000260,919261,000313,1000136,8870156,1000130,8870118,8980142,7520224,000069,0320172,146093,2840132,989093,8220113,37800000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
65,000
0
100,000
0
150,000
0
150,000
0
25,000
0
80,000
0
120,000
0
120,000
0
155,000
0
115,000
0
70,000
0
81,561
0
51,624
0
0
0
0
60,000
60,000
60,000
60,000
60,000
60,000
50,000
50,000
50,000
50,000
20,000
20,000
0
53,023
0
101,023
0
80,000
0
95,000
0
94,990
94,990095,000080,0000101,023053,023020,00020,00050,00050,00050,00050,00060,00060,00060,00060,00060,00060,000000051,624081,561070,0000115,0000155,0000120,0000120,000080,000025,0000150,0000150,0000100,000065,00000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,000
5,000
7,000
7,000
12,090
12,090
15,026
15,026
26,449
26,449
34,719
34,719
26,570
4,593
28,295
28,295
26,682
26,682
32,394
32,394
29,451
29,451
64,447
64,447
38,606
38,606
38,60638,60664,44764,44729,45129,45132,39432,39426,68226,68228,29528,2954,59326,57034,71934,71926,44926,44915,02615,02612,09012,0907,0007,0005,0005,000000000000000000000000000000000000000000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,392
0
14,561
0
12,546
0
14,867
0
18,258
0
22,901
0
16,175
0
13,451
0
12,269
0
15,484
0
13,567
0
10,694
0
10,562
7,000
11,797
7,000
15,063
4,537
16,627
1,906
19,056
4,467
30,916
2,574
37,327
5,369
31,939
8,972
37,291
8,342
35,024
8,170
40,613
6,949
36,400
5,136
69,583
7,693
46,299
46,2997,69369,5835,13636,4006,94940,6138,17035,0248,34237,2918,97231,9395,36937,3272,57430,9164,46719,0561,90616,6274,53715,0637,00011,7977,00010,562010,694013,567015,484012,269013,451016,175022,901018,258014,867012,546014,56107,39200000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20,695
0
19,418
0
16,976
0
16,877
0
17,677
0
16,246
0
15,170
0
14,067
0
13,590
0
12,959
0
12,807
0
14,262
0
13,870
0
62,649
0
59,264
0
58,570
0
58,189
0
57,628
0
7,013
0
7,381
0
36,607
0
36,045
0
6,266
0
6,987
0
6,201
0
24,284
24,28406,20106,98706,266036,045036,60707,38107,013057,628058,189058,570059,264062,649013,870014,262012,807012,959013,590014,067015,170016,246017,677016,877016,976019,418020,69500000000000000000000000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,669
0
16,541
0
15,617
0
15,433
0
16,171
0
15,059
0
14,377
0
13,409
0
13,043
0
12,469
0
12,157
0
11,166
0
10,724
0
9,645
0
8,878
8,280
8,280
7,768
7,768
7,106
7,106
6,424
6,424
5,750
5,750
6,062
5,162
4,483
1,683
5,275
5,248
3,767
3,772
2,923
32,100
21,619
21,644
21,64421,61932,1002,9233,7723,7675,2485,2751,6834,4835,1626,0625,7505,7506,4246,4247,1067,1067,7687,7688,2808,2808,87809,645010,724011,166012,157012,469013,043013,409014,377015,059016,171015,433015,617016,541017,66900000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50,000
50,000
50,000
50,000
50,000
50,000
50,000
50,000
50,000
50,000
0
0
0
0
30,000
30,000
0
0
0
0
0
0
0
0
0
0
000000000030,00030,000000050,00050,00050,00050,00050,00050,00050,00050,00050,00050,000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,053
0
1,517
0
997
0
1,076
0
1,160
0
0
0
600
0
0
0
432
0
0
0
224
0
188
0
346
0
267
0
232
202
202
326
326
246
246
372
372
384
384
372
372
0
589
0
672
0
467
0
632
0
1,247
1,2470632046706720589037237238438437237224624632632620220223202670346018802240004320006000001,16001,076099701,51702,05300000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
88
88
95
95
276
276
217
217
1,247
1,247
173
173
973
973
319
319
363
363
2,646
2,646
152
152
1521522,6462,6463633633193199739731731731,2471,247217217276276959588880000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
108,880
0
150,658
0
106,302
0
86,079
0
83,821
0
69,132
0
269,843
0
247,180
0
228,883
0
202,217
0
199,446
0
204,829
0
383,879
355,000
354,624
363,000
362,758
344,549
344,549
392,605
392,605
363,331
363,331
348,438
348,438
315,632
315,632
314,427
314,427
0
276,631
0
331,840
0
305,928
0
305,874
0
303,239
303,2390305,8740305,9280331,8400276,6310314,427314,427315,632315,632348,438348,438363,331363,331392,605392,605344,549344,549362,758363,000354,624355,000383,8790204,8290199,4460202,2170228,8830247,1800269,843069,132083,821086,0790106,3020150,6580108,88000000000000000000000000000000000
   > Total Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
34,811
0
98,985
0
57,550
0
39,929
0
34,054
0
30,987
0
58,613
0
55,320
0
60,306
0
53,154
0
61,690
0
64,543
0
68,836
64,000
64,016
73,000
72,914
79,059
79,059
79,491
79,491
62,359
62,359
66,684
66,684
81,354
81,354
75,494
75,494
37,823
37,823
50,161
50,161
37,707
37,707
174,408
174,408
155,443
155,443
155,443155,443174,408174,40837,70737,70750,16150,16137,82337,82375,49475,49481,35481,35466,68466,68462,35962,35979,49179,49179,05979,05972,91473,00064,01664,00068,836064,543061,690053,154060,306055,320058,613030,987034,054039,929057,550098,985034,81100000000000000000000000000000000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,705
0
0
0
0
0
0
0
0
0
0
0
0
195,000
195,000
195,000
195,000
195,842
195,842
196,224
196,224
196,600
196,600
0
0
0
0
0
0
0
1,800
0
1,752
0
1,684
0
124,401
0
119,320
119,3200124,40101,68401,75201,8000000000196,600196,600196,224196,224195,842195,842195,000195,000195,000195,0000000000000001,70500000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
195,000
195,000
195,000
195,000
195,842
195,842
196,224
196,224
196,600
196,600
0
0
0
0
0
0
0
0
0
0
0
0
0
123,505
0
117,195
117,1950123,5050000000000000196,600196,600196,224196,224195,842195,842195,000195,000195,000195,000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,012
0
923
0
1,188
0
2,093
0
1,385
0
1,395
0
1,705
0
1,618
0
1,701
0
1,311
0
2,113
0
1,303
0
1,094
1,000
1,207
2,000
1,851
2,475
2,475
4,353
4,353
1,599
1,599
6,399
6,399
3,310
3,310
6,765
6,765
1,723
1,723
13,151
13,151
5,378
5,378
10,617
10,617
4,706
4,706
4,7064,70610,61710,6175,3785,37813,15113,1511,7231,7236,7656,7653,3103,3106,3996,3991,5991,5994,3534,3532,4752,4751,8512,0001,2071,0001,09401,30302,11301,31101,70101,61801,70501,39501,38502,09301,188092302,01200000000000000000000000000000000
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,799
0
98,062
0
56,362
0
37,836
0
32,669
0
29,592
0
55,203
0
53,702
0
58,604
0
51,843
0
59,577
0
63,240
0
67,742
51,000
62,809
56,000
71,063
55,784
76,584
55,538
75,138
36,460
60,760
33,585
60,285
58,544
78,044
43,829
68,729
14,400
34,300
13,958
35,258
13,445
30,645
11,490
39,390
15,317
31,417
31,41715,31739,39011,49030,64513,44535,25813,95834,30014,40068,72943,82978,04458,54460,28533,58560,76036,46075,13855,53876,58455,78471,06356,00062,80951,00067,742063,240059,577051,843058,604053,702055,203029,592032,669037,836056,362098,062032,79900000000000000000000000000000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
74,068
0
51,673
0
48,751
0
46,149
0
49,767
0
38,145
0
211,229
0
191,861
0
168,577
0
149,063
0
137,756
0
140,286
0
315,043
0
290,608
0
289,844
0
265,490
0
313,114
0
300,972
0
281,754
0
234,278
0
238,933
0
238,808
0
281,679
0
268,221
0
131,466
0
147,796
147,7960131,4660268,2210281,6790238,8080238,9330234,2780281,7540300,9720313,1140265,4900289,8440290,6080315,0430140,2860137,7560149,0630168,5770191,8610211,229038,145049,767046,149048,751051,673074,06800000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
197,358
0
197,740
0
198,118
0
239,668
0
227,869
0
94,544
0
0
0094,5440227,8690239,6680198,1180197,7400197,3580000000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
69,648
69,648
116,890
116,890
104,372
104,372
84,772
84,772
36,920
36,920
40,693
40,693
39,690
39,690
41,115
41,115
40,264
40,264
36,912
36,912
35,807
35,807
35,80735,80736,91236,91240,26440,26441,11541,11539,69039,69040,69340,69336,92036,92084,77284,772104,372104,372116,890116,89069,64869,6480000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
97,729
0
78,356
0
210,241
0
192,932
0
153,269
0
121,286
0
105,502
0
43,090
0
70,874
0
72,113
0
57,931
0
44,049
0
14,856
0
-8,971
0
-35,000
-50,651
-50,651
-41,440
-41,440
-58,223
-58,223
-66,687
-66,687
-79,983
-79,983
-92,960
-92,960
0
-79,576
0
-102,046
0
-78,752
0
-58,607
0
-67,166
-67,1660-58,6070-78,7520-102,0460-79,5760-92,960-92,960-79,983-79,983-66,687-66,687-58,223-58,223-41,440-41,440-50,651-50,651-35,0000-8,971014,856044,049057,931072,113070,874043,0900105,5020121,2860153,2690192,9320210,241078,356097,72900000000000000000000000000000000
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,585
0
9,585
0
9,587
0
9,588
0
9,588
0
9,588
0
9,588
0
9,598
0
10,200
0
10,478
0
10,575
0
10,789
0
10,801
918,000
11,810
922,000
11,812
11,850
11,850
11,872
11,872
11,879
11,879
11,879
11,879
11,880
11,880
11,882
11,882
11,920
11,920
11,922
11,922
12,931
12,931
12,992
12,992
12,999
12,999
12,99912,99912,99212,99212,93112,93111,92211,92211,92011,92011,88211,88211,88011,88011,87911,87911,87911,87911,87211,87211,85011,85011,812922,00011,810918,00010,801010,789010,575010,478010,20009,59809,58809,58809,58809,58809,58709,58509,58500000000000000000000000000000000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000-24,1000-23,8000-39,0000-39,2000-38,6000-38,2000-37,3000-36,6000-36,3000-35,6000-35,2000-34,0000-34,000000-32,500000-30,900000-29,729000-28,617000-27,13100000000000000000000000000000000
   Capital Surplus 00000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00-56,5590-56,3090-52,7660-6,8750-5,9630-7,4190000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
861,986
0
839,965
0
873,741
0
836,821
0
864,371
0
837,227
0
870,808
0
794,771
0
870,187
0
858,079
0
899,915
0
915,935
0
919,417
0
922,902
0
920,937
-24,100
926,112
-19,204
934,797
-18,600
938,537
-16,281
939,278
-15,998
942,012
-24,555
935,824
-24,141
924,029
-27,252
926,520
-24,973
944,596
-21,617
951,620
-20,506
955,263
955,263-20,506951,620-21,617944,596-24,973926,520-27,252924,029-24,141935,824-24,555942,012-15,998939,278-16,281938,537-18,600934,797-19,204926,112-24,100920,9370922,9020919,4170915,9350899,9150858,0790870,1870794,7710870,8080837,2270864,3710836,8210873,7410839,9650861,98600000000000000000000000000000000



Balance Sheet

Currency in CHF. All numbers in thousands.




Cash Flow

Currency in CHF. All numbers in thousands.